华润医药(03320.HK)：博雅生物上半年净利润2.25亿元 同比下降28.68%

Core Viewpoint - China Resources Pharmaceutical (03320.HK) announced that Boya Bio (300294.SZ) achieved a revenue of 1.008 billion yuan in the first half of 2025, representing a year-on-year growth of 12.51%. However, the net profit attributable to shareholders decreased by 28.68% to 225 million yuan, and the net profit excluding non-recurring gains and losses fell by 36.05% to 166 million yuan, with basic earnings per share at 0.45 yuan [1]. Financial Performance - Boya Bio's revenue for the first half of 2025 reached 1.008 billion yuan, marking a 12.51% increase compared to the previous year [1]. - The net profit attributable to shareholders was 225 million yuan, which is a decline of 28.68% year-on-year [1]. - The net profit excluding non-recurring gains and losses stood at 166 million yuan, reflecting a decrease of 36.05% year-on-year [1]. - Basic earnings per share were reported at 0.45 yuan [1].